

Special Issue

Vaccines for Ebola Virus and Related Diseases

Message from the Guest Editor

I am pleased to invite you to prepare a contribution to our upcoming special issue on vaccines for Ebola virus disease (EVD) and related diseases. EVD is an important disease in sub-Saharan Africa, reaching its historic clinical impact during 2013–2016 West Africa epidemic. This topical issue of *Vaccines* welcomes contributions dealing with all aspects of the design, development, testing and administration of current and future vaccines for Ebola virus and related viruses including Marburg virus. We also welcome contributions dealing with Ebola vaccine policy and social issues relating to accessibility of vaccines, Ebola vaccine use during humanitarian crises, epidemiological methods for assessing Ebola vaccine efficacy and safety, preventive and reactive uses of the vaccine, vaccine distribution, vaccination of special groups including pregnant women, infants and children and persons with simultaneous co-infections, vaccines and sexual transmission, Ebola vaccine hesitancy, and other important topics relating to these life-saving vaccines.

Guest Editor

Dr. David A. Schwartz

Perinatal Pathology Consulting, Atlanta, GA, USA

Deadline for manuscript submissions

closed (31 December 2020)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



mdpi.com/si/39378

Vaccines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the second half of 2024).